Obesity drug development is advancing at unprecedented speed, but demonstrating weight loss or clinical efficacy alone is no longer enough to support long-term success. In this webinar, gain insight into how to design obesity trials that generate clinically meaningful, patient-relevant and payer-relevant evidence.
As obesity therapies evolve beyond weight loss toward broader metabolic, cardiovascular and patient-centered outcomes, sponsors face growing pressure to design trials that generate evidence relevant not only to regulators, but also to payers, providers and patients.
From endpoint selection and patient stratification to long-term outcomes and real-world applicability, obesity studies increasingly require integrated evidence strategies that support differentiation, reimbursement and sustainable access in a highly competitive market.
This webinar brings together cross-functional experts to explore how sponsors can design obesity trials that deliver both clinical and commercial value. The discussion will examine how development teams can align trial design, endpoint strategy, patient selection and evidence generation with evolving stakeholder expectations across the healthcare ecosystem.
Attendees will learn how to:
- Select endpoints that extend beyond weight reduction to demonstrate meaningful metabolic, cardiovascular, functional and quality-of-life outcomes while incorporating the patient voice into evidence generation and endpoint strategy
- Design patient-centric obesity trials that better reflect real-world populations, treatment adherence and long-term disease management, including the generation of evidence supporting long-term adherence and weight maintenance
- Incorporate payer-relevant evidence strategies early in development to support reimbursement, health technology assessment (HTA) and market access
- Leverage real-world evidence and longitudinal data to strengthen value demonstration and differentiation
- Align clinical development, medical affairs, HEOR and commercial strategy around integrated evidence generation
- Address the growing demand for durable outcomes data and evidence supporting long-term healthcare impact
Register for this webinar to gain a practical framework for designing obesity trials that move beyond regulatory success toward real-world impact. Learn how to generate evidence that supports patient outcomes, payer confidence and long-term commercial value.
Speakers
Leslie Harrold, MD, MPH, Vice President & Head, Real World Science and Strategy, Prospective Real-World Studies, Thermo Fisher Scientific
Dr. Leslie Harrold is a physician, epidemiologist and outcomes researcher with extensive experience generating real-world evidence to improve patient care and inform healthcare decision-making. She has authored more than 150 peer-reviewed publications focused on the patient experience, medication adherence, medication safety and effectiveness and quality of care.
As Vice President and Head of Real World Science and Strategy for the Prospective Real-World Studies business of Thermo Fisher Scientific, Dr. Harrold leads a multidisciplinary team of more than 80 epidemiologists and biostatisticians. She oversees the scientific strategy and execution of real-world evidence programs that address complex biomedical and therapeutic questions for life sciences companies, regulators, healthcare providers and other stakeholders. This work helps contextualize the clinical landscape by evaluating the effectiveness and safety of therapeutics in routine clinical practice, both overall and within specific patient subgroups. These insights inform drug development, evidence-generation strategies and treatment decisions across the product lifecycle.
Message Presenter
Hayley Karn, PhD, CPsychol, Senior Research Scientist, PPD Evidera Patient-Centered Research, Thermo Fisher Scientific
Dr. Hayley Karn is a senior research scientist with over 15 years’ experience in the design, management, interpretation and reporting of health outcomes studies. Currently leading the Obesity Working Group and responsible for overseeing all aspects of a large portfolio of in-trial research (ITR) and clinical outcome assessment (COA) projects in obesity, Dr. Karn has extensive expertise incorporating the patient voice into the development of obesity medications. Authored works include ‘Baby Food Matters’ and ‘An Appetite for Life,’ and she conducted a PhD in Behavioral Nutrition at University College London focusing on the relationship between appetite, dietary intake and pediatric weight gain. With prior roles including qualitative researcher for an NIHR funded project evaluating the National Child Measurement Programme (NCMP) in the UK, and an internship with Danone Nutricia Early Life Nutrition, Dr. Karn has built a solid foundation in evaluating health interventions and contributing to the epidemiology and treatment of obesity.
Message Presenter
Almudena Olid Gonzalez, MA, Director, Market Access, PPD Evidera Health Economics and Market Access, Thermo Fisher Scientific
Almudena Olid Gonzalez specializes in market access strategy, with a particular focus on evidence generation planning and value demonstration to support timely patient access and commercial success.
Prior to her current role, Almudena worked at two consulting firms, where she led global market access projects across a wide range of therapeutic areas, including diabetes and obesity. Her experience spans multiple product categories, including cell and gene therapies, biosimilars, vaccines and medical devices, across diverse international markets.
Almudena also served as a Pricing Manager at Norgine BV, where she led the Global Pricing Committee. Her responsibilities included setting price corridors, conducting pricing analyses across direct and partner markets and aligning pricing decisions with market dynamics and product value. She also supported local affiliates in developing business cases and managed the company’s global pricing database.
Today, Almudena plays a key role in projects related to health technology assessment (HTA) methods and policy. Her work has included Integrated Scientific Advice, HTA implementation in major European markets, HTA landscape assessments, EU HTA Regulation organizational design and implementation readiness, PICO development and prediction and EU HTA Regulation training programs. She has also led and supported evidence generation strategy and planning initiatives designed to inform strategic decision-making and facilitate patient access.
Message Presenter
Firas M. Dabbous, PhD, MS, Senior Research Scientist, PPD Evidera Real-World Data & Scientific Solutions, Thermo Fisher Scientific
Firas M. Dabbous is an epidemiologist and health outcomes researcher with extensive experience designing and conducting real-world evidence studies using administrative claims, electronic health records, chart reviews and survey datasets.
Dr. Dabbous has served as a principal investigator and epidemiologist on observational research studies, database analyses and literature reviews across multiple therapeutic areas, including cardiometabolic diseases, oncology, infectious diseases and rare diseases. Prior to his current role, he held leadership roles in patient-centered outcomes research and health economics and outcomes research (HEOR) at Advocate Health Care, AbbVie and Creativ-Ceutical.
He has authored and co-authored numerous peer-reviewed publications and scientific presentations. Dr. Dabbous earned a PhD in Epidemiology from the University of Illinois Chicago, an MS in Statistics from the University of Southern Maine and a BS in Mathematics from Beirut Arab University.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Clinical development and translational leaders designing obesity and metabolic disease trials
- Medical affairs and scientific strategy leaders supporting obesity evidence generation
- HEOR, market access and payer strategy professionals responsible for reimbursement and value demonstration
- Biostatistics, outcomes research and real-world evidence teams supporting endpoint and evidence strategy
- Regulatory leaders shaping obesity trial design and long-term outcomes planning
- Commercial and portfolio strategy leaders aligning clinical differentiation with market access needs
- Program leadership and cross-functional development teams advancing integrated obesity programs
- Pharmaceutical, biotechnology and life sciences organizations developing obesity and metabolic therapies
What You Will Learn
By attending this webinar, attendees will learn how to:
- Design obesity trials that generate clinically meaningful, patient-relevant and payer-relevant evidence
- Select endpoints that demonstrate broader metabolic, cardiovascular and patient-centered value
- Improve patient selection and trial design to better reflect real-world obesity management
- Integrate real-world evidence and longitudinal outcomes into obesity development programs
- Build cross-functional evidence strategies that support reimbursement, differentiation and long-term access
- Position obesity therapies for success in an increasingly outcomes-driven healthcare environment
Xtalks Partner
The PPD clinical research business of Thermo Fisher Scientific Inc.
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, enables customers to accelerate innovation and increase drug development productivity. Utilizing patient-centered strategies and data analytics, their capabilities cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, novel approaches to patient recruitment and investigator sites, and comprehensive laboratory services. Recognized as a global industry leader in accelerating promising medicines from early development through regulatory approval and market access, they serve pharma, biotech, medical device and government organizations with custom-tailored solutions, including full-service partnerships and functional service partnerships. As a strategic partner in clinical development and analytical services, they apply cutting edge technologies, therapeutic expertise and a firm commitment to quality to help customers deliver life-changing therapies.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account